

ACCESS • EDUCATION • HOPE

# THE ONCIDIUM FOUNDATION

PROMOTE & SUPPORT THE DEVELOPMENT OF  
RADIOTHERANOSTICS

## In this issue:

What's up Oncidium  
foundation?

Page 01

Latest RT news  
Page 02Close-up on Neuroendocrine  
Cancer UK  
Page 03Oncidium Ambassadors  
Page 032019 in retrospect  
Page 04Coming up next  
Page 04

### **Oncidium foundation during COVID-19: working remotely**

Now more than ever, the COVID-19 pandemic goes to show that everyone is and must be concerned when it comes to health issues. Thus, continuing the everyday efforts to support and promote life-saving technologies, such as Radiotheranostics for cancer therapy, is crucial to reach the long-term goal of enhancing global access.

Take care of yourselves and your loved ones.

### **Oncidium foundation paper anniversary**

#### **Looking back on one year of activities**

Time flies, as it's been a year since Oncidium 2.0 team was formed and activities were started. Founded by Dr. Richard Zimmermann in 2011, the new team endeavors to promote the use of Radiotheranostics to cure cancer.

To sum up 2019: new dream team, precious encounters, emerging collaborations and hope to expand access to an innovative and life-saving technology.

#### **New year, new website!**

Explore the new website and discover how the Oncidium foundation can help you and how you can be of help. Register your hospital, become the best advocate and connection to patients, share your knowledge or learn more, suggest new projects, translate the website in your local language... Spread the link and tell others about it, come back with questions (or with answers), or become an Oncidium Ambassador in your country!

All these possibilities and more, visit:

[www.oncidiumfoundation.org](http://www.oncidiumfoundation.org)

# Latest news


## Highlights in the Radiotheranostics field

*The key is.... Access • Education • Hope*

### 31<sup>st</sup> of March: Happy World Theranostics Day!

This key date is coined with the first therapy with radioiodine administered to a patient in 1941 at Massachusetts General Hospital. 79 years later, Theranostics is an evolving field of Nuclear Medicine, with marked developments in precision medicine leading to improved patient care. On this occasion, the **SNNMI** underlined the recent highlights and future events that will enable the evolution of this life-saving technology.

The **EANM** also shared a review destined to inform practitioners on their value by establishing a roadmap for future developments. In fact, some products have already proven their worth and more radiopharmaceuticals will enter clinical practice in the coming years.



[www.linkedin.com/feed/update/urn:li:activity:6650761377650667521/](https://www.linkedin.com/feed/update/urn:li:activity:6650761377650667521/)  
<https://www.linkedin.com/feed/update/urn:li:activity:6651407246108475392/>

*Improving...*

**Access • Education • Hope**

## Revolutionizing Prostate Cancer's Standard of Care

### Promising response <sup>177</sup>Lu-PSMA

**Misr Radiology, Egypt** - A picture is worth a thousand words: a case of metastatic castration-resistant prostate cancer post a single dose of <sup>177</sup>Lu-PSMA radioactive dose.




Image provided by Misr Radiology Center in Cairo, Egypt.

### <sup>225</sup>Ac-PSMA-617/<sup>177</sup>Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience

**Saarland University, Germany** - First promising results on a pilot experience suggest that a single course of tandem therapy with low-activity <sup>225</sup>Ac-PSMA-617/full-activity <sup>177</sup>Lu-PSMA-617 may safely enhance response to PSMA-targeted Radioligand therapy in men with late-stage/end-stage metastatic castration-resistant prostate cancer while minimizing xerostomia severity.

Source: Eur J Nucl Med Mol Imaging 47, 721–728 (2020). <https://doi.org/10.1007/s00259-019-04612-0>

### PSMA PET-CT in patients with high-risk prostate cancer

**Peter MacCallum Cancer Center, Australia** - ProPSMA study results explained by Professor Michael Hofman are definitive that <sup>68</sup>Ga-PSMA PET-CT is better than and can replace conventional imaging with CT and bone scan (Accuracy: PSMA PET/CT showed 27% superiority) for staging men with high-risk prostate cancer before surgery or radiotherapy with curative intent.

Source: VOLUME 395, ISSUE 10231, P1208-1216, APRIL 11, 2020 [https://doi.org/10.1016/S0140-6736\(20\)30314-7](https://doi.org/10.1016/S0140-6736(20)30314-7)

# Close-up on Neuroendocrine Cancer UK

## The Oncidium foundation extends its support to Neuroendocrine Cancer UK



Being diagnosed with cancer, let alone rare or uncommon types is a great challenge for cancer patients and their loved ones. Formerly NET Patient Foundation, NCUK is dedicated to providing support and information to those affected by Neuroendocrine cancers. Their work is manifested in various forms: support and inform patients and their families from diagnosis, enabling access to the best care and treatment, whilst stimulating Neuroendocrine Cancer research, increasing national awareness and influencing improvements in outcomes.

A charity for... Support Groups | Advocacy | Education | Awareness | Research  
To learn more: [www.neuroendocrinecancer.org.uk](http://www.neuroendocrinecancer.org.uk)

## Oncidium foundation Ambassadors

### Expanding access worldwide, better, together!

One of the great achievements over the past year was the expansion of the Oncidium foundation network, specially thanks to the Oncidium Ambassadors. Building it is necessary to the pursuit of the mission: expanding access to Radiotheranostics globally. The foundation cannot act alone to be efficient and reach as many people as possible. The solution is to build a worldwide network of Ambassadors in each country for awareness and education campaigns, local collaborations, shared knowledge etc.



**Rosanne Robinson**  
Ambassador | **Australia**




**Dr. Guilherme Rossi**  
Ambassador | **Brazil**



**Denio Mustrangi**  
Sub-delegate | **Brazil**



**Dr. Yehia Omar**  
Ambassador | **Egypt**



**Dr. Ivan E. Diaz Meneses**  
Ambassador | **Mexico**



**Dr. Batool Albalooshi**  
Ambassador | **UAE**



**Learn more and become an Oncidium Ambassador:**


[www.ovidiumfoundation.org/patient/volunteer/](http://www.ovidiumfoundation.org/patient/volunteer/)



# Promoting Radiotheranostics: 2019 in retrospect

## Looking back at major events and moving forward

### Looking Back and Moving Forward: International Symposium on the occasion of the 20th Anniversary of Molecular Radiotherapy at Zentralklinik Bad Berka & Inauguration of the ICPO Foundation



**Bad Berka, Germany (December 2019)** - Lead by Pr. Richard Baum, the Symposium gathered in the same room the top scientists and practitioners in the field of Radiotheranostics.

As a consensus, the need to understand the disease of the patient at its best before any decision making. Hopefully most of the initiatives are taking that direction, starting with clinical trials with real-time data in real-world patients (RWD) (cfr. Prof J. Harvey Turner), going through the development of new Theranostics ligands with Multi-Tumor-Tracer properties (FAPI - Fibroblast Activation Protein Inhibitor-based radiopharmaceutical) but also Peptide Receptor Radionuclide Therapy (PRRT) improvements (performing dosimetry, cell sensitivity, possible combinations, etc).

Developments around Radiotheranostics have progressed exponentially over the past years. Hence, the importance of supporting research and helping low income countries to equip themselves with the latest technologies (with the help of organizations like the ICPO Foundation for example).

### Annual Conference of Society of Nuclear Medicine India

**Mumbai, India (December 2019)** - Rebecca Lo bue, General Manager of the Oncidium foundation had the opportunity to present the mission and projects of the Oncidium foundation during the SNMICON meeting in Mumbai.

The specialty of nuclear medicine in India is growing very rapidly. The emergence of molecular imaging which include SPECT and PET technology has brought forward exciting new possibilities for clinical applications as well as radioligand therapy (PRRT).



### Arab Health 2020

**Dubai, UAE (January 2020)** - First glimpse at the Middle Eastern healthcare market. Discovering the numerous halls sets the mood: the world of healthcare is infinite, busy and full of demand, offers and possibilities. Meeting Oncidium's Ambassador in the UAE for the first time. Exchanging with foundations, industrials and practitioners about the life-saving potential of Radioligand therapies.

Conclusion: now, more than ever, Radiotheranostics technology must pursue efforts and emerge as a major player among cancer treatments, which takes the idea of the Oncidium foundation to new heights.

### EANM focus meeting 3 about Theranostics in NET

**Athens, Greece (January 2020)** - Great opportunity to have an in-depth overview of the current and future directions in the management of Neuroendocrine tumors imaging and therapy with a focus on the role of neuroimaging in Nuclear Medicine.

## Coming up next

**SNMMI 2020:** June 13 - 16  
New Orleans, USA

**ESTRO 2020:** July 31 - August 04  
Vienna, Austria

**ESMO 2020:** September 18 - 22  
Madrid, Spain

**EANM 2020:** October 17 - 20  
Vienna, Austria

**Register your hospital:**

[www.onscidiumfoundation.org/register/](http://www.onscidiumfoundation.org/register/)



**The Oncidium foundation**  
Rue Emile Francqui 6 (boîte 5)  
BE-1435 Mont-Saint-Guibert, Belgium

[contact@onscidium-life.org](mailto:contact@onscidium-life.org)

[www.onscidiumfoundation.org](http://www.onscidiumfoundation.org)

